Expanded Access Program (EAP) STIMULAN VG
- Conditions
- Stage IV Pressure UlcerDiabetic Foot Osteomyelitis
- Registration Number
- NCT06808568
- Lead Sponsor
- Biocomposites Ltd
- Brief Summary
Individual (single) patient expanded access may be considered.
- Detailed Description
Patients facing serious or life-threatening illnesses who have exhausted currently available treatment options and are ineligible or unable to participate in a clinical trial may decide to explore therapeutic use of investigational drugs with their healthcare providers.
Under these circumstances, single-patient access can be requested from a licensed treating physician on behalf of the patient.
Please contact expandedaccess@biocomposites.com for more information.
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Exclusion Criteria
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does STIMULAN VG promote tissue regeneration in Stage IV pressure ulcers and diabetic foot osteomyelitis?
What is the comparative effectiveness of STIMULAN VG versus standard-of-care treatments for Stage IV pressure ulcers and diabetic foot osteomyelitis?
Which biomarkers predict response to STIMULAN VG in patients with Stage IV pressure ulcers and diabetic foot osteomyelitis?
What are the known or potential adverse events associated with STIMULAN VG use in EAP settings?
What are the key competitor drugs or combination therapies for treating Stage IV pressure ulcers and diabetic foot osteomyelitis?